Pseudogene OCT4-pg5 upregulates OCT4B expression to promote bladder cancer progression by competing with miR-145-5p

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Teoh JYC, Huang J, Ko WYK, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 2020;78(6):893–906. doi: 10.1016/j.eururo.2020.09.006
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8(3):420–444. doi: 10.1001/jamaoncol.2021.6987
   PubMed Web of Science ®Google Scholar
• Patra SK. Roles of OCT4 in pathways of embryonic development and cancer progression. Mech Ageing Dev. 2020;189:111286. doi: 10.1016/j.mad.2020.111286
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao Y, Xiao Z, et al. Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. Stem Cells. 2009;27(6):1265–1275. doi: 10.1002/stem.58
   PubMed Web of Science ®Google Scholar
• Chen S, Zhu J, Wang F, et al. LncRNAs and their role in cancer stem cells. Oncotarget. 2017;8(66):110685–110692. doi: 10.18632/oncotarget.22161
   PubMedGoogle Scholar
• Lu CS, Shieh GS, Wang CT, et al. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget. 2017;8(19):30844–30858. doi: 10.18632/oncotarget.9602
   PubMedGoogle Scholar
• Iskender B, Izgi K, Canatan H. And canatan H reprogramming bladder cancer cells for studying cancer initiation and progression. Tumour Biol. 2016;37(10):13237–13245. doi: 10.1007/s13277-016-5226-4
   PubMedGoogle Scholar
• Poursani EM, Mehravar M, Shahryari A, et al. Alternative splicing generates different 5’ UTRs in OCT4B variants. Avicenna J Med Biotechnol. 2017;9(4):201–204.
   PubMedGoogle Scholar
• Lin SC, Chung CH, Chung CH, et al. OCT4B mediates hypoxia-induced cancer dissemination. Oncogene. 2019;38(7):1093–1105. doi: 10.1038/s41388-018-0487-6
   PubMed Web of Science ®Google Scholar
• Meng L, Hu H, Zhi H, et al. OCT4B regulates p53 and p16 pathway genes to prevent apoptosis of breast cancer cells. Oncol Lett. 2018;16(1):522–528. doi: 10.3892/ol.2018.8607
   PubMed Web of Science ®Google Scholar
• Poursani EM, Mehravar M, Mohammad Soltani B, et al. A novel variant of OCT4 entitled OCT4B3 is expressed in human bladder cancer and astrocytoma cell lines. Avicenna J Med Biotechnol. 2017;9(3):142–145.
   PubMedGoogle Scholar
• Choi SH, Kim JK, Jeon HY, et al. OCT4B isoform promotes anchorage-independent growth of glioblastoma cells. Mol Cells. 2019;42(2):135–142. doi: 10.14348/molcells.2018.0311
   PubMed Web of Science ®Google Scholar
• Xu WX, Liu Z, Deng F, et al. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res. 2019;11(11):6739–6753.
   PubMed Web of Science ®Google Scholar
• Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010;102(5):883–891. doi: 10.1038/sj.bjc.6605570
   PubMed Web of Science ®Google Scholar
• Zhu J, Qin P, Cao C, et al. Use of miR145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Oncol Rep. 2021;45(3):963–974. doi: 10.3892/or.2021.7925
   PubMed Web of Science ®Google Scholar
• Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015. doi: 10.3390/cells8091015
   PubMed Web of Science ®Google Scholar
• Taheri M, Omrani MD, Ghafouri-Fard S. Long non-coding RNA expression in bladder cancer. Biophys Rev. 2018;10(4):1205–1213. doi: 10.1007/s12551-017-0379-y
   PubMedGoogle Scholar
• Hirotsune S, Yoshida N, Chen A, et al. An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene. Nature. 2003;423(6935):91–96. doi: 10.1038/nature01535
   PubMed Web of Science ®Google Scholar
• Hu X, Yang L, Mo YY. Role of pseudogenes in tumorigenesis. Cancers (Basel). 2018;10(8):256. doi: 10.3390/cancers10080256
   PubMed Web of Science ®Google Scholar
• Poursani EM, Mohammad Soltani B, Mowla SJ. Differential expression of OCT4 pseudogenes in pluripotent and tumor cell lines. Cell J. 2016;18(1):28–36. doi: 10.22074/cellj.2016.3984
   PubMed Web of Science ®Google Scholar
• Bai M, Yuan M, Liao H, et al. OCT4 pseudogene 5 upregulates OCT4 expression to promote proliferation by competing with miR-145 in endometrial carcinoma. Oncol Rep. 2015;33(4):1745–1752. doi: 10.3892/or.2015.3763
   PubMed Web of Science ®Google Scholar
• Suo G, Han J, Wang X, et al. Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun. 2005;337(4):1047–1051. doi: 10.1016/j.bbrc.2005.09.157
   PubMed Web of Science ®Google Scholar
• Khan AQ, Ahmed EI, Elareer NR, et al. Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells. 2019;8(8):840. doi: 10.3390/cells8080840
   PubMed Web of Science ®Google Scholar
• Yoshida T, Kates M, Fujita K, et al. Predictive biomarkers for drug response in bladder cancer. Int J Urol. 2019;26(11):1044–1053. doi: 10.1111/iju.14082
   PubMed Web of Science ®Google Scholar
• Lenfant L, Aminsharifi A, Seisen T, et al. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer. Curr Opin Urol. 2020;30(3):428–440. doi: 10.1097/MOU.0000000000000740
   PubMed Web of Science ®Google Scholar
• D’Andrea D, Matin S, Black PC, et al. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021;127(5):528–537. doi: 10.1111/bju.15253
   PubMed Web of Science ®Google Scholar
• Chan JJ, Tay Y. Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):1310. doi: 10.3390/ijms19051310
   PubMed Web of Science ®Google Scholar
• Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18. doi: 10.1038/nrc.2017.99
   PubMed Web of Science ®Google Scholar
• Mohapatra S, Pioppini C, Ozpolat B, et al. Non-coding RNAs regulation of macrophage polarization in cancer. Mol Cancer. 2021;20(1):24. doi: 10.1186/s12943-021-01313-x
   PubMed Web of Science ®Google Scholar
• Li C, Xu N, Li YQ, et al. Inhibition of SW620 human colon cancer cells by upregulating miRNA-145. World J Gastroenterol. 2016;22(9):2771–2778. doi: 10.3748/wjg.v22.i9.2771
   PubMed Web of Science ®Google Scholar
• Azizmohammadi S, Safari A, Azizmohammadi S, et al. Molecular identification of miR-145 and miR-9 expression level as prognostic biomarkers for early-stage cervical cancer detection. QJM. 2017;110(1):11–15. doi: 10.1093/qjmed/hcw101
   PubMed Web of Science ®Google Scholar
• Xu N, Papagiannakopoulos T, Pan G, et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647–658. doi: 10.1016/j.cell.2009.02.038
   PubMed Web of Science ®Google Scholar
• Soheili S, Asadi MH, Farsinejad A. Distinctive expression pattern of OCT4 variants in different types of breast cancer. Cancer Biomark. 2017;18(1):69–76. doi: 10.3233/CBM-160675
   PubMed Web of Science ®Google Scholar
• Lou W, Ding B, Fu P. Pseudogene-derived lncRnas and their miRNA sponging mechanism in human cancer. Front Cell Dev Biol. 2020;8:85. doi: 10.3389/fcell.2020.00085
   PubMed Web of Science ®Google Scholar
• Wang L, Guo ZY, Zhang R, et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis. 2013;34(8):1773–1781. doi: 10.1093/carcin/bgt139
   PubMed Web of Science ®Google Scholar
• Poliseno L, Salmena L, Zhang J, et al. A coding-independent function of gene and pseudogene mRnas regulates tumour biology. Nature. 2010;465(7301):1033–1038. doi: 10.1038/nature09144
   PubMed Web of Science ®Google Scholar
• Matsushita R, Yoshino H, Enokida H, et al. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness. Oncotarget. 2016;7(19):28460–28487. doi: 10.18632/oncotarget.8668
   PubMedGoogle Scholar
• Wu Y, Liu S, Xin H, et al. Retracted: up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer. 2011;117(17):3989–3998. doi: 10.1002/cncr.25944
   PubMed Web of Science ®Google Scholar
• Zhou JM, Hu SQ, Jiang H, et al. OCT4B1 promoted EMT and regulated the self-renewal of CSCs in CRC: effects associated with the balance of miR-8064/PLK1. Mol Ther Oncolytics. 2019;15:7–20. doi: 10.1016/j.omto.2019.08.004
   PubMed Web of Science ®Google Scholar
• Zhao H, Kang X, Xia X, et al. miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am J Transl Res. 2016;8(7):3106–3114.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang Z, Li K, et al. Author correction: linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells. Cell Death Dis. 2019;10(8):604. doi: 10.1038/s41419-019-1852-2
   PubMedGoogle Scholar
• Li C, Lu L, Feng B, et al. Retracted Article: the lincRNA-ROR/miR-145 axis promotes invasion and metastasis in hepatocellular carcinoma via induction of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep. 2017;7(1):4637. doi: 10.1038/s41598-017-04113-w
   PubMedGoogle Scholar
• Sun L, Liu T, Zhang S, et al. Oct4 induces EMT through LEF1/β-catenin dependent WNT signaling pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(4):2599–2606. doi: 10.3892/ol.2017.5788
   PubMed Web of Science ®Google Scholar
• Liu L, Zhu H, Liao Y, et al. Inhibition of Wnt/β-catenin pathway reverses multi-drug resistance and EMT in Oct4+/Nanog+ NSCLC cells. Biomed Pharmacother. 2020;127:110225. doi: 10.1016/j.biopha.2020.110225
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European Association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi: 10.1016/j.eururo.2020.03.055
   PubMed Web of Science ®Google Scholar
• Drayton RM, Catto JW. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther. 2012;12(2):271–281. doi: 10.1586/era.11.201
   PubMed Web of Science ®Google Scholar
• Liu X, Ma M, Duan X, et al. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. Clin Transl Oncol. 2017;19(5):587–592. doi: 10.1007/s12094-016-1569-y
   PubMed Web of Science ®Google Scholar
• Chiou SH, Wang ML, Chou YT, et al. Coexpression of Oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70(24):10433–10444. doi: 10.1158/0008-5472.CAN-10-2638
   PubMed Web of Science ®Google Scholar
• de Vries G, Rosas-Plaza X, van Vugt MATM, et al. Testicular cancer: determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treat Rev. 2020;88:102054. doi: 10.1016/j.ctrv.2020.102054
   PubMedGoogle Scholar